Urology is a medical/surgical specialty involving the diagnosis and treatment of acute and chronic disorders of the urinary tract and male reproductive organs. 

This report focuses on the therapeutic management of the most common non-oncologic conditions affecting male urology including:  benign prostatic hyperplasia (BPH), erectile dysfunction (ED), incontinence, prostatitis, and urinary calculus (stone) disease.  These conditions afflict a substantial population of men in the United States (U.S.)—the ED population alone is estimated at more than 30 million.  Unfortunately, most patients remain underserved and undertreated.  This is projected to change over the next five years due to greater patient awareness and the emergence of more effective, less-invasive therapies.  In particular, the largest population of “actively treated” male urology patients in the year 2008 will be ED patients, which will increase nearly 9% annually to an estimated 12 million.

In 2003, therapeutic urology products were employed in the management of more than 12.4 million male patients, generating an estimated $3.4 billion in total drug and device revenues.  Approximately 80% of sales were contributed by BPH and ED treatment products, followed by prostatitis drugs (11.5%), urinary stone removal systems (7.5%), and urinary stress incontinence surgical devices (less than 1.0%).

The total U.S. market for urologic therapy products is projected to grow approximately 8% per year from $3.4 billion in 2003 to a substantial market size of $4.9 billion in the year 2008.  The most significant gains are expected in the BPH and ED management product segments, based on the development of improved BPH-specific “combination” drugs, new and improved oral and transdermal ED drugs, and the accelerated patient migration to minimally invasive, less traumatic BPH thermotherapy. 

This dynamic report from Medtech Insight includes analyses of pharmaceuticals, medical devices/disposables and equipment and presents competitors, current and forecast markets, and opportunities in the U.S. market for male therapeutic urology products.  Covered topics include BPH-specific drugs; electrosurgery disposables; minimally invasive thermotherapy systems; prostatic stents; ED drugs, erection-assist devices; penile implants; prostatitis drugs; extracorporeal and intracorporeal lithotripsy systems; ureteral stents; urinary tract access and stone retrieval devices; artificial urinary sphincters; injectable bulking agents, and male sling systems.

TABLE OF CONTENTS

EXECUTIVE SUMMARY

i.   Benign Prostatic Hyperplasia Therapy Products Market

ii.   Erectile Dysfunction Therapy Products Market

iii.  Prostatitis Therapy Products Market

iv.  Urinary Incontinence Therapy Products Market

v.  Urinary Stone Removal and Management Market

1. ETIOLOGY AND EPIDEMIOLOGY OF COMMON UROLOGIC DISORDERS

1.1 Benign Prostatic Hyperplasia

1.1.1 Symptoms

1.1.2 Causes

1.1.3 Diagnosis

1.1.4 Treatment

1.1.5 Prevalence

1.2 Erectile Dysfunction

1.2.1 Causes

1.2.1.1 Organic Causes

1.2.1.2 Psychogenic Causes

1.2.2 Diagnosis

1.2.3 Treatment

1.2.4 Prevalence

1.3 Prostatitis

1.3.1 Types and Symptoms

1.3.2 Causes

1.3.3 Diagnosis

1.3.4 Treatment

1.3.5 Incidence and Prevalence

1.4 Urinary Incontinence

1.4.1 Types and Causes

1.4.1.1 Urge Incontinence

1.4.1.2 Stress Urinary Incontinence

1.4.1.3 Mixed Incontinence

1.4.1.4 Overflow Incontinence

1.4.1.5 Other Types of Incontinence

1.4.2 Diagnosis

1.4.3 Treatment

1.4.4 Prevalence

1.5 Urinary Stone Disease

1.5.1 Types and Causes

1.5.2 Symptoms

1.5.3 Diagnosis

1.5.4 Treatment

1.5.5 Incidence

2. BENIGN PROSTATIC HYPERPLASIA THERAPY PRODUCTS MARKET

2.1 Established Therapeutic Approaches

2.1.1 Watchful Waiting

2.1.2 Drug Therapy

2.1.2.1 Alpha Blockers

2.1.2.2 5-Alpha-Reductase Inhibitors

2.1.2.3 Combination Drug Therapy

2.1.2.4 Patient Caseload Forecast

2.1.3 Surgical Treatment

2.1.3.1 Transurethral Resection of the Prostate

2.1.3.2 Transurethral Incision of the Prostate

2.1.3.3 Transurethral Vaporization of the Prostate

2.1.3.4 Procedure Volumes Forecast

2.1.4 Minimally Invasive Directed Energy-Based Therapy

2.1.4.1 Transurethral Microwave Thermotherapy

2.1.4.2 Transurethral Needle Ablation

2.1.4.3 Laser-Based Therapy

2.1.4.3.1 Holmium Laser Enucleation of the Prostate

2.1.4.3.2 Interstitial Laser Coagulation

2.1.4.3.3 Photo-Selective Vaporization of the Prostate

2.1.4.3.4 Video Laser-Assisted Prostatectomy

2.1.4.4 High-Intensity Focused Ultrasound Therapy

2.1.4.5 Water-Induced Thermotherapy

2.1.4.6 Procedure Volumes Forecast

2.1.5 Prostatic Stents

2.1.5.1 Procedure Volumes Forecast

2.2 Market Analysis

2.2.1 Drug Therapy

2.2.1.1 Market Forecast

2.2.1.2 Competitive Analysis

2.2.2 Electrosurgery Disposables

2.2.2.1 Market Forecast

2.2.2.2 Competitive Analysis

2.2.3 Minimally Invasive Directed Energy-Based Therapy

2.2.3.1 Market Forecast

2.2.3.2 Competitive Analysis

2.2.4 Prostatic Stents

2.2.4.1 Market Forecast

2.2.4.2 Competitive Analysis

3. ERECTILE DYSFUNCTION THERAPY PRODUCTS MARKET

3.1 Current and Emerging Treatments

3.1.1 Current Drug Therapy

3.1.1.1 Oral Drug Therapy

3.1.1.2 Injectable Drug Therapy

3.1.1.3 Intraurethral Drug Therapy

3.1.1.4 Emerging Drug Therapy

3.1.1.4.1 Centrally Acting Agents

3.1.1.4.2 Transdermal Drugs

3.1.1.5 Patient Caseload Forecast

3.1.2 Vacuum Constriction Devices

3.1.2.1 Patient Caseload Forecast

3.1.3 Penile Prosthetic Implants

3.1.3.1 Malleable Penile Implants

3.1.3.2 Inflatable Penile Prostheses

3.1.3.3 Procedure Volumes Forecast

3.1.4 Investigational Surgical Approaches

3.1.4.1 Implantable Electrical Stimulators

3.1.4.2 Microsurgical Nerve Grafting

3.1.4.3 Multiple Percutaneous Occlusion Techniques

3.1.4.4 Surgical Revascularization

3.2 Market Analysis

3.2.1 Drug Therapy

3.2.1.1 Market Forecast

3.2.1.2 Competitive Analysis

3.2.2 Vacuum Constriction Devices

3.2.2.1 Market Forecast

3.2.2.2 Competitive Analysis

3.2.3 Penile Implant Systems

3.2.3.1 Market Forecast

3.2.3.2 Competitive Analysis

4. PROSTATITIS THERAPY PRODUCTS MARKET

4.1 Current Treatments

4.1.1 Drug Therapy

4.1.1.1 Anti-Infectives

4.1.1.2 Anti-Inflammatory and Analgesic Agents

4.1.1.3 Narcotic Drugs

4.1.1.4 Alpha-Adrenergic Blockers

4.1.2 Conservative Non-Pharmacologic Therapy

4.1.3 Surgical Interventions in Prostatitis Patients

4.1.4 Minimally Invasive Thermotherapy

4.1.4.1 Microwave Thermotherapy

4.1.4.1.1 Transrectal Microwave Thermotherapy

4.1.4.1.2 Transurethral Microwave Thermotherapy

4.1.4.2 Transurethral Needle Ablation

4.1.4.3 Water-Induced Thermotherapy

4.2 Market Analysis

5. URINARY INCONTINENCE THERAPY PRODUCTS MARKET

5.1 Established Therapeutic Approaches

5.1.1 Behavioral and Physiotherapeutic Rehabilitation

5.1.1.1 Toileting Assistance

5.1.1.2 Bladder Training

5.1.1.3 Pelvic Muscle Rehabilitation

5.1.2 Drug Therapy for Urge Incontinence

5.1.2.1 Anticholinergics/Antispasmodics

5.1.2.2 Tricyclics

5.1.2.3 Calcium Channel Blockers

5.1.3 Drug Therapy Options for Stress Urinary Incontinence

5.1.4 Drug Therapy Options for Overflow Incontinence

5.1.5 Device-Based Surgical Therapy for Stress Urinary Incontinence

5.1.5.1 Bulking Agent Implants

5.1.5.1.1 Contigen

5.1.5.1.2 Durasphere

5.1.5.1.3 Procedure Volumes Forecast

5.1.5.2 Male Sling Procedure

5.1.5.2.1 Procedure Volumes Forecast

5.1.5.3 Artificial Urinary Sphincter Implantation

5.1.5.3.1 Procedure Volumes Forecast

5.2 Device-Based Surgical Therapy for Stress Urinary Incontinence, Market Analysis

5.2.1 Bulking Agent Implants

5.2.1.1 Market Forecast

5.2.1.2 Competitive Analysis

5.2.2 Male Sling Systems

5.2.2.1 Market Forecast

5.2.2.2 Competitive Analysis

5.2.3 Artificial Urinary Sphincter Devices, Market Forecast

6. URINARY STONE REMOVAL AND MANAGEMENT PRODUCTS MARKET

6.1 Established Therapeutic Approaches, Treatment Systems and Devices

6.1.1 Extracorporeal Shock Wave Lithotripsy

6.1.1.1 Procedure Volumes Forecast

6.1.2 Endoscopic Stone Removal

6.1.2.1 Procedure Volumes Forecast

6.1.3 Percutaneous Nephrolithotomy

6.1.3.1 Procedure Volumes Forecast

6.1.4 Intracorporeal Lithotripsy

6.1.4.1 Electrohydraulic Lithotripsy

6.1.4.2 Laser Lithotripsy

6.1.4.3 Pneumatic Lithotripsy

6.1.4.4 Ultrasonic Lithotripsy

6.1.4.5 Procedure Volumes Forecast

6.1.5 Urinary Tract Access and Stone Retrieval Systems

6.1.5.1 Renal and Ureteral Access Devices

6.1.5.1.1 Nephroscopes

6.1.5.1.2 Ureteroscopes

6.1.5.2 Urinary Stone Retrieval Devices

6.1.5.2.1 Stone Baskets

6.1.5.2.2 Stone Graspers

6.1.5.2.3 Ureteral Balloon Dilation Catheters

6.1.6 Open Surgery

6.1.6.1 Procedure Volumes Forecast

6.1.7 Ureteral Stenting

6.1.7.1 Insertion Techniques

6.1.7.2 Indwelling Time

6.1.7.3 Procedure Volumes Forecast

6.2 Market Analysis

6.2.1 Extracorporeal Shockwave Lithotripsy Systems

6.2.1.1 Market Forecast

6.2.1.2 Competitive Analysis

6.2.2 Intracorporeal Lithotripsy Systems

6.2.2.1 Market Forecast

6.2.2.2 Competitive Analysis

6.2.3 Urinary Tract Access and Stone Retrieval Systems

6.2.3.1 Market Forecast

6.2.3.2 Competitive Analysis

6.2.4 Ureteral Stents

6.2.4.1 Market Forecast

6.2.4.2 Competitive Analysis

7. COMPANY PROFILES

7.1   Abbott Laboratories

7.2   ACMI Corporation/Fox Paine & Company LLC

7.3   American Medical Systems, Inc.

7.4   C.R. Bard, Inc.

7.5   Boston Scientific Corporation

7.6   Cook Group, Inc.

7.7   Dornier MedTech GmbH

7.8   Endocare, Inc.

7.9   GlaxoSmithKline PLC

7.10 Johnson & Johnson

7.11 Karl Storz GmbH & Company KG

7.12 Medtronic, Inc.

7.13 Mentor Corporation

7.14 Merck & Company, Inc.

7.15 Olympus America, Inc./Olympus Corporation

7.16 Pfizer, Inc.

7.17 Siemens Medical Solutions USA, Inc./Siemens AG

7.18 Urologix, Inc

APPENDIX:  COMPANY LISTING

LIST OF EXHIBITS

Exhibit ES-1:    Common Male Urologic Disorders, Estimated Incidence and Prevalence, 2003 and 2008

Exhibit ES-2:    Male Urology Therapy, Patient Treatment Forecast, 2003-2008

Exhibit ES-3:    Male Urology Therapy Products, Market Forecast, 2003-2008

Exhibit ES-4:    Benign Prostatic Hyperplasia Therapy, Patient Treatment Forecast, 2003-2008

Exhibit ES-5:    Benign Prostatic Hyperplasia Therapy Products, Market Forecast, 2003-2008

Exhibit ES-6:    Erectile Dysfunction, Patient Caseload Forecast, by Therapy Type, 2003-2008

Exhibit ES-7:    Erectile Dysfunction Therapy Products, Market Forecast, by Therapy Type, 2003-2008

Exhibit ES-8:    Prostatitis Therapy, Patient Treatment Forecast, 2003-2008

Exhibit ES-9:    Prostatitis Drug Therapy and Thermotherapy Products, Market Forecast, 2003-2008

Exhibit ES-10:   Male Stress Urinary Incontinence Surgical Therapy, Procedure Volumes Forecast, 2003-2008

Exhibit ES-11:   Male Stress Urinary Incontinence Surgical Therapy Products, Market Forecast, 2003-2008

Exhibit ES-12:   Urinary Stone Removal and Management, Procedure Volumes Forecast, 2003-2008

Exhibit ES-13:   Urinary Stone Removal and Management Products, Market Forecast, 2003-2008

Exhibit 1-1:      2003, Benign Prostatic Hyperplasia, Facts and Figures

Exhibit 1-2:      2003, Erectile Dysfunction, Facts and Figures

Exhibit 1-3:      2003, Prostatitis, Facts and Figures

Exhibit 1-4:      2003, Male Urinary Incontinence, Facts and Figures

Exhibit 1-5:      2003, Urinary Stone Disease, Facts and Figures

Exhibit 1-6:      Common Male Urologic Disorders, Estimated Incidence and Prevalence, 2003 and 2008

Exhibit 2-1:      Benign Prostatic Hyperplasia Drug Therapy, Patient Caseload Forecast, 2003-2008

Exhibit 2-2:      Electrosurgical Transurethral Prostatectomy, Procedure Volumes Forecast, 2003-2008

Exhibit 2-3:      Minimally Invasive Directed Energy-Based Benign Prostatic Hyperplasia Therapy, Procedure Volumes Forecast, 2003-2008

Exhibit 2-4:      Prostatic Stenting, Procedure Volumes Forecast, 2003-2008

Exhibit 2-5:      Benign Prostatic Hyperplasia Therapy, Patient Caseload and Procedure Volumes Forecast, 2003-2008

Exhibit 2-6:      Benign Prostatic Hyperplasia Therapy Products, Market Forecast, 2003-2008

Exhibit 2-7:      Benign Prostatic Hyperplasia Drug Therapy Products, Market Forecast, 2003-2008

Exhibit 2-8:      2004, Selected Benign Prostatic Hyperplasia Drugs

Exhibit 2-9:      2003, Benign Prostatic Hyperplasia Drug Therapy Products Market, Share by Supplier

Exhibit 2-10:     Electrosurgical Transurethral Prostatectomy Disposables, Market Forecast, 2003-2008

Exhibit 2-11:     2003, Electrosurgical Transurethral Prostatectomy Disposables Market, Share by Supplier

Exhibit 2-12:     Minimally Invasive Directed Energy-Based Benign Prostatic Hyperplasia Therapy Products, Market Forecast, 2003-2008

Exhibit 2-13:     2004, Selected Minimally Invasive Directed Energy-Based Benign Prostatic Hyperplasia Therapy Systems

Exhibit 2-14:     2003, Minimally Invasive Directed Energy-Based Benign Prostatic Hyperplasia Therapy Systems Market, Share by Supplier

Exhibit 2-15:     Prostatic Stents, Market Forecast, 2003-2008

Exhibit 2-16:     2004, Selected Current and Emerging Prostatic Stents

Exhibit 3-1:      Erectile Dysfunction Drug Therapy, Patient Caseload Forecast, 2003-2008

Exhibit 3-2:      Vascular Constriction Devices, Patient Caseload Forecast, 2003-2008

Exhibit 3-3:      Penile Implants, Procedure Volumes Forecast, 2003-2008

Exhibit 3-4:      Erectile Dysfunction, Patient Caseload Forecast, by Therapy Type, 2003-2008

Exhibit 3-5:      Erectile Dysfunction Therapy Products, Market Forecast, by Therapy Type, 2003-2008

Exhibit 3-6:      Erectile Dysfunction Drug Therapy Products, Market Forecast, 2003-2008

Exhibit 3-7:      2004, Selected Current and Emerging Erectile Dysfunction Drugs

Exhibit 3-8:      2003, Oral Erectile Dysfunction Drugs Market, Share by Supplier

Exhibit 3-9:      2003, Injectable Erectile Dysfunction Drugs Market, Share by Supplier

Exhibit 3-10:     Vacuum Constriction Devices, Market Forecast, 2003-2008

Exhibit 3-11:     2004, Selected Vacuum Constriction Devices

Exhibit 3-12:     2003, Vacuum Constriction Devices Market, Share by Supplier

Exhibit 3-13:     Penile Implants, Market Forecast, 2003-2008

Exhibit 3-14:     2004, Selected Penile Implant Systems

Exhibit 3-15:     2003, Penile Implants Market, Share by Supplier

Exhibit 4-1:      Prostatitis Treatment, Minimally Invasive Thermotherapy, Selected Clinical Trial Data

Exhibit 4-2:      Prostatitis Treatment, Advantages and Disadvantages of Minimally Invasive Thermotherapy

Exhibit 4-3:      Prostatitis Therapy, Patient Treatment Forecast, 2003-2008

Exhibit 4-4:      Prostatitis Drug Therapy and Thermotherapy Products, Market Forecast, 2003-2008

Exhibit 5-1:      Bulking Agent Implantation, Procedure Volumes Forecast, 2003-2008

Exhibit 5-2:      Bone-Anchored Bulbourethral Male Slings, Procedure Volumes Forecast, 2003-2008

Exhibit 5-3:      Artificial Urinary Sphincter Implantation, Procedure Volumes Forecast, 2003-2008

Exhibit 5-4:      Male Stress Urinary Incontinence Surgical Therapy, Procedure Volumes Forecast, 2003-2008

Exhibit 5-5:      Male Stress Urinary Incontinence Surgical Therapy Products, Market Forecast, 2003-2008

Exhibit 5-6:      Bulking Agent Implants, Market Forecast, 2003-2008

Exhibit 5-7:      2004, Selected Current and Emerging Bulking Agent Implants

Exhibit 5-8:      2003, Bulking Agent Implants Market, Share by Supplier

Exhibit 5-9:      Bone-Anchored Bulbourethral Male Slings, Market Forecast, 2003-2008

Exhibit 5-10:     2003, Bone-Anchored Bulbourethral Male Slings Market, Share by Supplier

Exhibit 5-11:     Artificial Urinary Sphincter Systems, Market Forecast, 2003-2008

Exhibit 6-1:      Extracorporeal Shockwave Lithotripsy, Procedure Volumes Forecast, 2003-2008

Exhibit 6-2:      Endoscopic Stone Removal, Procedure Volumes Forecast, 2003-2008

Exhibit 6-3:      Percutaneous Nephrolithotomy, Procedure Volumes Forecast, 2003-2008

Exhibit 6-4:      Intracorporeal Lithotripsy, Procedure Volumes Forecast, 2003-2008

Exhibit 6-5:      Open Surgical Stone Removal, Procedure Volumes Forecast, 2003-2008

Exhibit 6-6:      Ureteral Stenting, Procedure Volumes Forecast, 2003-2008

Exhibit 6-7:      Urinary Stone Removal and Management, Procedure Volumes Forecast, by Type, 2003-2008

Exhibit 6-8:      Urinary Stone Removal and Management Products, Market Forecast, by Type, 2003-2008

Exhibit 6-9:      Extracorporeal Shockwave Lithotripsy Systems, Market Forecast, 2003-2008

Exhibit 6-10:     2004, Selected Extracorporeal Shockwave Lithotriptors

Exhibit 6-11:     2003, Extracorporeal Shockwave Lithotriptors Market, Share by Supplier

Exhibit 6-12:     Intracorporeal Lithotripsy Systems, Market Forecast, 2003-2008

Exhibit 6-13:     2004, Selected Intracorporeal Lithotripsy Systems

Exhibit 6-14:     2003, Intracorporeal Lithotripsy Systems Market, Share by Supplier

Exhibit 6-15:     Urinary Tract Access and Stone Retrieval Devices, Market Forecast, 2003-2008

Exhibit 6-16:     2004, Selected Urinary Tract Access and Stone Retrieval Devices

Exhibit 6-17:     2003, Urinary Tract Access Devices Market, Share by Supplier

Exhibit 6-18:     2003, Urinary Stone Retrieval Devices Market, Share by Supplier

Exhibit 6-19:     Ureteral Stents, Market Forecast, 2003-2008

Exhibit 6-20:     2004, Selected Ureteral Stents

Exhibit 6-21:     2003, Ureteral Stents Market, Share by Supplier

Copyright 2005, Medtech Insight, LLC